• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Allosteric regulation and inhibition of protein kinases.别构调节和蛋白激酶抑制。
Biochem Soc Trans. 2023 Feb 27;51(1):373-385. doi: 10.1042/BST20220940.
2
Networks for the allosteric control of protein kinases.用于蛋白激酶变构控制的网络
Curr Opin Struct Biol. 2006 Dec;16(6):686-92. doi: 10.1016/j.sbi.2006.10.011. Epub 2006 Nov 7.
3
Allosteric Regulation of Protein Kinases Downstream of PI3-Kinase Signalling.PI3K 信号下游蛋白激酶的变构调节。
Adv Exp Med Biol. 2019;1163:279-311. doi: 10.1007/978-981-13-8719-7_12.
4
Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors.利用蛋白激酶的结构多样性和变构调节机制发现小分子抑制剂
Curr Med Chem. 2017;24(42):4838-4872. doi: 10.2174/0929867323666161006113418.
5
Orthosteric and allosteric modulation of human kinases: A mechanistic view.正向变构调节和人源激酶的别构调节:一种机制观点。
Front Biosci (Landmark Ed). 2020 Mar 1;25(8):1462-1487. doi: 10.2741/4864.
6
Hierarchical Organization Endows the Kinase Domain with Regulatory Plasticity.层次组织赋予激酶结构域以调节可塑性。
Cell Syst. 2018 Oct 24;7(4):371-383.e4. doi: 10.1016/j.cels.2018.08.008. Epub 2018 Sep 19.
7
Gaining Insights into Key Structural Hotspots within the Allosteric Binding Pockets of Protein Kinases.深入了解蛋白激酶别构结合口袋中的关键结构热点。
Int J Mol Sci. 2024 Apr 26;25(9):4725. doi: 10.3390/ijms25094725.
8
Engineering allosteric regulation in protein kinases.工程化蛋白激酶的别构调控。
Sci Signal. 2018 Nov 6;11(555):eaar3250. doi: 10.1126/scisignal.aar3250.
9
Interrogating Regulatory Mechanisms in Signaling Proteins by Allosteric Inhibitors and Activators: A Dynamic View Through the Lens of Residue Interaction Networks.通过别构抑制剂和激活剂探究信号蛋白中的调控机制:基于残基相互作用网络的动态视角。
Adv Exp Med Biol. 2019;1163:187-223. doi: 10.1007/978-981-13-8719-7_9.
10
Dual roles of ATP-binding site in protein kinases: Orthosteric inhibition and allosteric regulation.ATP 结合位点在蛋白激酶中的双重作用:变构抑制和变构调节。
Adv Protein Chem Struct Biol. 2021;124:87-119. doi: 10.1016/bs.apcsb.2020.09.005. Epub 2021 Feb 13.

引用本文的文献

1
How residence time works in allosteric drugs.变构药物中的驻留时间是如何起作用的。
Curr Opin Struct Biol. 2025 Aug 29;94:103149. doi: 10.1016/j.sbi.2025.103149.
2
Target Mapping in Cancer: Ligandable Protein Pockets on 3D OncoPPI Networks.癌症中的靶点映射:3D肿瘤蛋白质-蛋白质相互作用网络上的可配体结合蛋白口袋
Pharmaceuticals (Basel). 2025 Jun 25;18(7):958. doi: 10.3390/ph18070958.
3
Drug resistance and tumor heterogeneity: cells and ensembles.耐药性与肿瘤异质性:细胞与细胞群体
Biophys Rev. 2025 May 31;17(3):759-779. doi: 10.1007/s12551-025-01320-y. eCollection 2025 Jun.
4
Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition.癌症治疗中的创新方法:强调纳米材料在酪氨酸激酶抑制中的作用。
Pharmaceutics. 2025 Jun 16;17(6):783. doi: 10.3390/pharmaceutics17060783.
5
Allosteric Coupling in Full-Length Lyn Kinase Revealed by Molecular Dynamics and Network Analysis.分子动力学和网络分析揭示全长Lyn激酶中的变构偶联
Int J Mol Sci. 2025 Jun 18;26(12):5835. doi: 10.3390/ijms26125835.
6
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies.用于B细胞恶性肿瘤的布鲁顿酪氨酸激酶(BTK)抑制剂及下一代BTK靶向疗法。
Arch Pharm Res. 2025 May 8. doi: 10.1007/s12272-025-01546-0.
7
ERK Allosteric Activation: The Importance of Two Ordered Phosphorylation Events.细胞外信号调节激酶的变构激活:两个有序磷酸化事件的重要性
J Mol Biol. 2025 Apr 9:169130. doi: 10.1016/j.jmb.2025.169130.
8
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.通过深度突变扫描绘制MET受体酪氨酸激酶的激酶结构域耐药机制图谱。
Elife. 2025 Feb 17;13:RP101882. doi: 10.7554/eLife.101882.
9
An SH3-binding allosteric modulator stabilizes the global conformation of the AML-associated Src-family kinase, Hck.一种与SH3结合的变构调节剂可稳定与急性髓系白血病相关的Src家族激酶Hck的整体构象。
J Biol Chem. 2025 Jan;301(1):108088. doi: 10.1016/j.jbc.2024.108088. Epub 2024 Dec 13.
10
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.通过深度突变扫描绘制MET受体酪氨酸激酶的激酶结构域耐药机制图谱。
bioRxiv. 2024 Dec 5:2024.07.16.603579. doi: 10.1101/2024.07.16.603579.

本文引用的文献

1
The protein kinase CK1: Inhibition, activation, and possible allosteric modulation.蛋白激酶CK1:抑制、激活及可能的别构调节
Front Mol Biosci. 2022 Aug 24;9:916232. doi: 10.3389/fmolb.2022.916232. eCollection 2022.
2
Validation of an Allosteric Binding Site of Src Kinase Identified by Unbiased Ligand Binding Simulations.通过无偏配体结合模拟鉴定Src 激酶的别构结合位点的验证。
J Mol Biol. 2022 Sep 15;434(17):167628. doi: 10.1016/j.jmb.2022.167628. Epub 2022 May 17.
3
Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1.变构药物与正构药物联合使用克服T315I BCR-ABL1耐药性的机制研究
Front Pharmacol. 2022 Mar 18;13:862504. doi: 10.3389/fphar.2022.862504. eCollection 2022.
4
Oral surveillance and JAK inhibitor safety: the theory of relativity.口腔监测与 JAK 抑制剂安全性:相对论。
Nat Rev Rheumatol. 2022 May;18(5):301-304. doi: 10.1038/s41584-022-00767-7. Epub 2022 Mar 22.
5
Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode.选择性磷酸肌醇 5-磷酸 4-激酶 γ 抑制剂的开发:一种非 ATP 竞争的别构结合模式。
J Med Chem. 2022 Feb 24;65(4):3359-3370. doi: 10.1021/acs.jmedchem.1c01819. Epub 2022 Feb 11.
6
Conformational switches that control the TEC kinase - PLCγ signaling axis.控制TEC激酶-PLCγ信号轴的构象开关。
J Struct Biol X. 2022 Jan 22;6:100061. doi: 10.1016/j.yjsbx.2022.100061. eCollection 2022.
7
Overcoming therapy resistance in EGFR-mutant lung cancer.克服 EGFR 突变型肺癌的治疗抵抗。
Nat Cancer. 2021 Apr;2(4):377-391. doi: 10.1038/s43018-021-00195-8. Epub 2021 Apr 15.
8
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.风湿免疫领域的 Janus 激酶靶向治疗:一种基于机制的方法。
Nat Rev Rheumatol. 2022 Mar;18(3):133-145. doi: 10.1038/s41584-021-00726-8. Epub 2022 Jan 5.
9
GCN2 kinase activation by ATP-competitive kinase inhibitors.GCN2 激酶被 ATP 竞争型激酶抑制剂激活。
Nat Chem Biol. 2022 Feb;18(2):207-215. doi: 10.1038/s41589-021-00947-8. Epub 2021 Dec 23.
10
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.使用CDK2/4/6抑制剂扩大对肿瘤细胞周期的控制。
Cancer Cell. 2021 Oct 11;39(10):1404-1421.e11. doi: 10.1016/j.ccell.2021.08.009. Epub 2021 Sep 13.

别构调节和蛋白激酶抑制。

Allosteric regulation and inhibition of protein kinases.

机构信息

Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11794, U.S.A.

出版信息

Biochem Soc Trans. 2023 Feb 27;51(1):373-385. doi: 10.1042/BST20220940.

DOI:10.1042/BST20220940
PMID:36794774
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10089111/
Abstract

The human genome encodes more than 500 different protein kinases: signaling enzymes with tightly regulated activity. Enzymatic activity within the conserved kinase domain is influenced by numerous regulatory inputs including the binding of regulatory domains, substrates, and the effect of post-translational modifications such as autophosphorylation. Integration of these diverse inputs occurs via allosteric sites that relate signals via networks of amino acid residues to the active site and ensures controlled phosphorylation of kinase substrates. Here, we review mechanisms of allosteric regulation of protein kinases and recent advances in the field.

摘要

人类基因组编码了超过 500 种不同的蛋白激酶:具有严格调控活性的信号酶。在保守的激酶结构域内,酶的活性受到许多调节输入的影响,包括调节结构域、底物的结合以及翻译后修饰(如自身磷酸化)的影响。这些不同的输入通过别构位点进行整合,通过氨基酸残基网络将信号传递到活性位点,并确保激酶底物的受控磷酸化。在这里,我们回顾了蛋白激酶别构调节的机制以及该领域的最新进展。